Volume 28 Issue 6, June 2021
Cover Credit:Small and cell-type restricted promoters are important tools for basic and preclinical research, and clinical delivery of gene therapies. Human-DNA MiniPromoter Ple32 (CLDN5, 1,670 bp) was developed for specifi c expression in the endothelial cells of the bloodretina and blood-brain barrier. The image shows Ple32 driving emerald GFP expression (green), co-labeled with anti-CD31 an endothelial cell marker (red), confi rming blood vessel expression in the target endothelial cells that create the barrier. See paper by Korecki et al. in this issue of Gene Therapy.
